Ryan D. Cassaday on Muck Rack

Ryan D. Cassaday

Seattle
As seen in: Nature, Wiley Online Library, Taylor & Francis Online, The Lancet, Dove Medical Press, Healio, HemOnc Today, OncLive, Patient Power
Husband of Dr. Emily Stevens MD PhD. ALL Doctor. Product of 2 UW's. Tweets are mine and do not constitute medical advice.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ryan D.

Contact Ryan D., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Patients First: Navigating Asparaginase‐Based Treatment in Young Adults With Acute Lymphoblastic Leukemia

|
By Ryan D. Cassaday, Daniel DeAngelo
| Wiley Online Library
1 Plain Language Abstract This educational program gives healthcare professionals practical tools and information they can use to improve survival and quality of life for young adults living with acute lymphoblastic leukemia (ALL), a type of blood cancer. In the program, real people describe their experiences with ALL. Many young adults with ALL face challenges related to transportation, job and family stress, mental health, and long-term wellness.
Open in Who Shared Issue with article?

Optimizing Asparaginase Treatment for Adolescent and Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations

|
By Ibrahim Aldoss, Amir Ali, Ryan D. Cassaday, Emily Curran
| Wiley Online Library
Conflicts of Interest I.A. reports advisory board participation for Acentage, Adaptive, Amgen, Autolus, Jazz Pharmaceuticals, Kite, Pfizer, Syndax, and Takeda; consulting for Amgen, Jazz Pharmaceuticals, Pfizer, and Takeda; and research support from AbbVie, Jazz Pharmaceuticals, and MacroGenics. A.A. reports consulting and participation in advisory boards, speakers' bureau participation, and research funding from Jazz Pharmaceuticals.
Open in Who Shared Issue with article?

The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia | Bone Marrow Transplantation

|
By Chenyu Lin, Matthew Connor, Navneet Majhail, Aaron Logan, Anjali Advani, LaQuisa C Hill, Joshua P. Sasine, Melhem Solh, Catherine Lee, Jessica Leonard, Marlise R. Luskin, Veronika Bachanova, Vinod Pullarkat, Ryan D. Cassaday, Lori Muffly, Jozal Moore
| Nature
Abstract Brexucabtagene autoleucel (brexu-cel) is a chimeric antigen receptor T (CAR T) cell therapy approved for adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). We studied the impact of social determinants of health (SDoH) on outcomes of adults with B-ALL receiving brexu-cel. This retrospective analysis included adults (≥18 years) with R/R B-ALL treated with brexu-cel between 2021 and 2023.
Open in Who Shared Issue with article?
See all 37 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Ryan D.

Contact Ryan D., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified